{
    "guideline_identifier": "PIIS0923753423051037.txt",
    "cancer_focus": {
        "primary_cancer": "Ovarian Cancer",
        "related_syndrome_or_condition": "Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome"
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Early Stage (I-II)",
            "risk_group": "Fertility Preservation Candidates",
            "treatment_plans": [
                {
                    "clinical_context": "Stage IA LGSC/EC/Mucinous",
                    "recommendation_type": "Surgical",
                    "recommendation_content": "Unilateral salpingo-oophorectomy + comprehensive staging",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "Histology",
                            "status": "LGSC/EC/Mucinous",
                            "testing_guidance": "Expert pathology review required"
                        }
                    ],
                    "esmo_evidence_level": "IV A"
                },
                {
                    "clinical_context": "High-grade Endometrioid Carcinoma",
                    "recommendation_type": "Adjuvant Therapy",
                    "recommendation_content": "Carboplatin/paclitaxel chemotherapy",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "I A"
                }
            ]
        },
        {
            "staging_criteria": "Advanced Stage (III-IV)",
            "risk_group": "Resectable Disease",
            "treatment_plans": [
                {
                    "clinical_context": "Primary treatment",
                    "recommendation_type": "Surgical",
                    "recommendation_content": "Primary cytoreductive surgery (PDS) if complete resection achievable",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "I A"
                },
                {
                    "clinical_context": "Unresectable Disease/High Surgical Risk",
                    "recommendation_type": "Systemic Therapy",
                    "recommendation_content": "Neoadjuvant chemotherapy (NACT) + interval debulking surgery",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "I A"
                },
                {
                    "clinical_context": "First-Line Maintenance (BRCAm or GIS+)",
                    "recommendation_type": "Targeted Therapy",
                    "recommendation_content": "PARP inhibitor ± bevacizumab",
                    "treatment_line": "Maintenance",
                    "biomarker_requirements": [
                        {
                            "name": "BRCA1/2",
                            "status": "Mutated",
                            "testing_guidance": "Germline/somatic testing required for all non-mucinous HGSC"
                        },
                        {
                            "name": "GIS (HRD)",
                            "status": "Positive",
                            "testing_guidance": "Validated assays only for BRCAwt stage III-IV HGSC"
                        }
                    ],
                    "esmo_evidence_level": "I A"
                },
                {
                    "clinical_context": "First-Line Maintenance (BRCAwt/GIS-)",
                    "recommendation_type": "Targeted Therapy",
                    "recommendation_content": "Bevacizumab or PARP inhibitor (niraparib/rucaparib)",
                    "treatment_line": "Maintenance",
                    "biomarker_requirements": [
                        {
                            "name": "BRCA1/2",
                            "status": "Wild-type",
                            "testing_guidance": "Mandatory testing before PARPi initiation"
                        },
                        {
                            "name": "GIS (HRD)",
                            "status": "Negative",
                            "testing_guidance": "Required for therapy selection"
                        }
                    ],
                    "esmo_evidence_level": "I A"
                },
                {
                    "clinical_context": "Low-Grade Serous Carcinoma",
                    "recommendation_type": "Systemic Therapy",
                    "recommendation_content": "Paclitaxel/carboplatin ± bevacizumab → endocrine maintenance",
                    "treatment_line": "First-line",
                    "biomarker_requirements": [
                        {
                            "name": "ER",
                            "status": "Positive",
                            "testing_guidance": "Required for endocrine therapy decisions"
                        }
                    ],
                    "esmo_evidence_level": "III B"
                }
            ]
        },
        {
            "staging_criteria": "Recurrent Disease",
            "risk_group": "Platinum-Sensitive (PFI ≥6 months)",
            "treatment_plans": [
                {
                    "clinical_context": "Prior PARPi-Naïve",
                    "recommendation_type": "Systemic Therapy",
                    "recommendation_content": "Platinum-based combination → PARP inhibitor maintenance",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [
                        {
                            "name": "BRCA1/2",
                            "status": "Mutated",
                            "testing_guidance": "Required for PARPi eligibility"
                        }
                    ],
                    "esmo_evidence_level": "I A"
                },
                {
                    "clinical_context": "Prior Bevacizumab Exposure",
                    "recommendation_type": "Targeted Therapy",
                    "recommendation_content": "Platinum-based combination → bevacizumab rechallenge",
                    "treatment_line": "Second-line",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "I A"
                }
            ]
        },
        {
            "staging_criteria": "Recurrent Disease",
            "risk_group": "Platinum-Resistant (PFI <6 months)",
            "treatment_plans": [
                {
                    "clinical_context": "General",
                    "recommendation_type": "Systemic Therapy",
                    "recommendation_content": "Non-platinum agents (weekly paclitaxel, PLD, topotecan) ± bevacizumab",
                    "treatment_line": "Second-line+",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "I A"
                },
                {
                    "clinical_context": "Low-Grade Serous Carcinoma",
                    "recommendation_type": "Targeted Therapy",
                    "recommendation_content": "Trametinib or endocrine therapy",
                    "treatment_line": "Second-line+",
                    "biomarker_requirements": [
                        {
                            "name": "Histology",
                            "status": "LGSOC",
                            "testing_guidance": "Pathology confirmation required"
                        }
                    ],
                    "esmo_evidence_level": "I A"
                }
            ]
        },
        {
            "staging_criteria": "Special Populations",
            "risk_group": "Elderly/Frail Patients",
            "treatment_plans": [
                {
                    "clinical_context": "Treatment Selection",
                    "recommendation_type": "Adapted Therapy",
                    "recommendation_content": "Geriatric assessment-guided therapy; Weekly paclitaxel/carboplatin",
                    "treatment_line": "All lines",
                    "biomarker_requirements": [],
                    "esmo_evidence_level": "II A"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": [
        {
            "biomarker": "BRCA1/2",
            "clinical_significance": "Predicts PARP inhibitor efficacy; Mandatory for maintenance therapy eligibility"
        },
        {
            "biomarker": "GIS (HRD)",
            "clinical_significance": "Predicts PARP inhibitor response in BRCAwt advanced HGSC"
        },
        {
            "biomarker": "CA-125 KELIM",
            "clinical_significance": "Prognostic for NACT response; Early predictor of platinum resistance"
        },
        {
            "biomarker": "MMR/MSI",
            "clinical_significance": "Identifies Lynch syndrome in EC/CCC; Guides immunotherapy decisions"
        },
        {
            "biomarker": "ctDNA Reversion Mutations",
            "clinical_significance": "Predicts PARPi resistance in BRCAm patients post-treatment"
        },
        {
            "biomarker": "HER2",
            "clinical_significance": "Therapeutic target in mucinous carcinoma"
        }
    ]
}